GCM1 CRISPR Activation Plasmid (h): sc-403269-ACT

Human GCM1 (glial cells missing homolog 1) is a lineage-restricted transcription factor that plays a central role in trophoblast differentiation and placental development, including syncytiotrophoblast formation and regulation of genes involved in hormone production, cell fusion, and nutrient exchange. By binding specific promoter/enhancer elements, GCM1 integrates developmental signaling with transcriptional programs controlling cell fate commitment, invasion, and vascular remodeling at the maternal–fetal interface. Altered GCM1 expression or activity has been associated with placental dysfunction phenotypes and adverse pregnancy biology, making it relevant for studying pathways underlying impaired trophoblast maturation and placental insufficiency. Its downstream network intersects with stress, hypoxia, and growth-factor responsive transcriptional circuitry that can be modeled in trophoblast stem cells, placental organoids, and related epithelial contexts.

GCM1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous GCM1 expression without altering the underlying DNA sequence.

GCM1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the GCM1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the GCM1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous GCM1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native GCM1 locus and enabling the study of GCM1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of GCM1 pathway restoration in tumor cells with silenced or reduced GCM1 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.